Brief: Paion completes patient recruitment in phase III study with Remimazolam

PAION AG

12/04/2016 06:37

April 12(Reuters) - Paion AG  PA8G.DE : 
    * Announced on Monday successful completion of recruitment 
in the U.S. Phase III clinical trial of Remimazolam, an 
ultra-short-acting sedative/anesthetic, for procedural sedation 
in patients undergoing colonoscopy 
    * No drug-related serious adverse event has been reported 
 
     
  
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nEQ8XBQl0a 
     
 Further company coverage:  PA8G.DE   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))